Vyome Holdings (HIND) Form 4 shows 615,149 fully vested options

Rhea-AI Filing Summary

Vyome Holdings, Inc. reported an option grant to its President and CEO, Venkat Nelabhotla, who also serves as a director. On 11/13/2025 he received stock options to purchase 615,149 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, and these options were fully vested on the grant date under the company’s 2025 Equity Incentive Plan.

The filing also explains that, under a previously signed Merger Agreement, Raider Lifesciences Inc. merged into Vyome Therapeutics, Inc. on August 15, 2025, with Vyome Therapeutics becoming a subsidiary of the issuer. Following this transaction, the issuer was renamed Vyome Holdings, Inc., while Vyome Therapeutics continued as Vyome Therapeutics, Inc.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nelabhotla Venkateswarlu

(Last) (First) (Middle)

HARVARD SQUARE,

ONE MIFFLIN PLACE, SUITE 400

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vyome Holdings, Inc [ HIND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)(2)	$0.66	11/13/2025		A(1)(2)		615,149		11/13/2025	07/30/2035	Common Stock	615,149	$0	615,149	D

Explanation of Responses:

1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

2. Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Venkat Nelabhotla	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vyome Holdings (HIND) disclose in this Form 4 filing?

Vyome Holdings disclosed that its President and CEO, who is also a director, received fully vested stock options to purchase 615,149 shares of common stock at $0.66 per share on 11/13/2025 under the 2025 Equity Incentive Plan.

How many Vyome Holdings (HIND) shares are covered by the new stock options?

The options cover 615,149 shares of Vyome Holdings, Inc. common stock, as reported in the Form 4.

What is the exercise price of the Vyome Holdings (HIND) stock options granted?

The stock options granted to the reporting person have an exercise price of $0.66 per share.

When did the Vyome Holdings (HIND) options vest and under which plan were they granted?

The options were fully vested as of the grant date of 11/13/2025 and were granted under Vyome Holdings’ 2025 Equity Incentive Plan.

What merger transaction involving Vyome Holdings (HIND) is referenced in the Form 4?

The filing references a Merger Agreement under which, on August 15, 2025, Raider Lifesciences Inc. merged with and into Vyome Therapeutics, Inc., which survived as a subsidiary, and the issuer was renamed Vyome Holdings, Inc..

How were Vyome Therapeutics stock options treated in the merger with Vyome Holdings (HIND)?

Each option to purchase Vyome Therapeutics common stock outstanding immediately before the merger was automatically assumed by the issuer and converted into options to purchase shares of Vyome Holdings common stock.

What is the role of the reporting person at Vyome Holdings (HIND)?

The reporting person is identified as a Director and as an Officer, serving as President and CEO of Vyome Holdings, Inc.